Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis

Stefania Oliva, Manuela Gambella, Milena Gilestro, Vittorio Emanuele Muccio, Francesca Gay, Daniela Drandi, Simone Ferrero, Roberto Passera, Chiara Pautasso, Annalisa Bernardini, Mariella Genuardi, Francesca Patriarca, Elona Saraci, Maria Teresa Petrucci, Norbert Pescosta, Anna Marina Liberati, Tommaso Caravita, Concetta Conticello, Alberto Rocci, Pellegrino MustoMario Boccadoro, Giuseppe Antonio Palumbo, Paola Omedè

Research output: Contribution to journalArticle

Abstract

We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p = 0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.

Original languageEnglish
Pages (from-to)5924-5935
Number of pages12
JournalOncotarget
Volume8
Issue number4
DOIs
Publication statusPublished - 2017

Keywords

  • ASO-RQ-PCR
  • Flow cytometry
  • MRD
  • Myeloma
  • Novel agents

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis'. Together they form a unique fingerprint.

  • Cite this

    Oliva, S., Gambella, M., Gilestro, M., Muccio, V. E., Gay, F., Drandi, D., Ferrero, S., Passera, R., Pautasso, C., Bernardini, A., Genuardi, M., Patriarca, F., Saraci, E., Petrucci, M. T., Pescosta, N., Liberati, A. M., Caravita, T., Conticello, C., Rocci, A., ... Omedè, P. (2017). Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis. Oncotarget, 8(4), 5924-5935. https://doi.org/10.18632/oncotarget.12641